BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Sen. Dwayne T.D. San Nicolas on Wednesday introduced Bill 282-37, which seeks to remove the Praxis mathematics requirement from the Guam initial educator certificate, saying this would address the ...

Sen. Dwayne T.D. San Nicolas' Bill 282-37, which seeks to remove the Praxis core mathematics requirement from the Guam Educator Certification, drew support during a May 22 hearing. “I do not want to ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. More than 25% of the UC San Diego students placed in the school's lowest remedial math class ...

Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock dropped 4% on Thursday following the release of a critical short report from Culper Research questioning the company’s Phase 3 trial ...

For the past several years, America has been using its young people as lab rats in a sweeping, if not exactly thought-out, education experiment. Schools across the country have been lowering standards ...

Praxis Precision Medicines (NASDAQ:PRAX) continued to climb on Thursday, adding more than 200% in the afternoon session as Wall Street welcomed a late-stage trial success for lixacaltamide, its ...